Haleon PLC is ingrained in a strategic series of share transactions, bolstering its value with an executive-acquisition of shares and an ambitious share
buyback program. Meanwhile,
Pfizer has been whittling down its holdings, offloading more than £2.4B and going forth with the plan to discard a considerable stake of 540 Million shares. However, on completion of the major share buyback, Pfizer will possess roughly 24% stake in Haleon. The firm also witnesses some meaningful support from
BlackRock who made a marked adjustment to its stake. Other noted institutional investors including Oppenheimer Asset Management, Chartwell Investment Partners, and Crossmark Global Holdings have followed suit, enhancing Haleon's share value. Amid the share buybacks, the company's share price dipped by 1.1% which is a point of concern for investors. In other news, Sensodyne maker,
Haleon, aims to expand its stake in a China JV. Furthermore, there's reported high single-digit growth forecasted for Haleon's annual organic operating profit. Top line growth and outperformance has captured
Morgan Stanley's positive attention, buoying investment expectations in Haleon.
Haleon Stocks News Analytics from Wed, 17 Jan 2024 08:00:00 GMT to Fri, 15 Nov 2024 10:35:33 GMT -
Rating -3
- Innovation 5
- Information 8
- Rumor -4
